AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01424735
Drug: Mycobacterium w.(Mw)-freeze dried extract 0.5ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml of Mw in 500ml 0.9% normal saline administered over two hours as an infusion. 2ml(4mg/ml) of dexamethasone administered two hours prior to Mw administration
Trial: NCT00303498
Drug: Sitexsentin sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitaxsentan 100 mg (target dose) 0rally once daily. A 10-week Run-In Phase was conducted where dosing commenced at 25 mg daily for 2 weeks, and then was stepped up to 50 mg daily for 2 weeks, to 75 mg daily for 2 weeks and then to 100 mg daily for 2 weeks, with an additional 2-week stabilization period (10 weeks total) to a target study dose of 100 mg daily. During the Run-In Phase, if a subject was not able to tolerate upward dose titration to the target dose of 100 mg, the investigator may have elected to continue at the current dosage or reduce the dosage of sitaxsentan or placebo to the subject's immediate prior dose. During the Maintenance Phase, subjects received the highest titrated dose reached of study drug and continued it through the last day of Week M24 of the Maintenance Phase (14 weeks)- total study drug treatment duration= 6 months
Trial: NCT00303498
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo identical to the study drug in description, dose and duration
Trial: NCT01323192
Drug: JNS001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.
Trial: NCT01323192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo orally once daily for 8 weeks.
Trial: NCT00754884
Drug: intranasal saline solution plus glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily intranasal (one shot) saline solution plus glycerol for a period of 14 days
Trial: NCT01820481
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bid, PO, 12weeks
Trial: NCT00364884
Drug: ketoaminoacid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01248325
Drug: Luffa Operculate Nasal Solution 5mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
Trial: NCT01430390
Drug: Cyclophosphamide-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide-based chemotherapy regimen will be the preferred conditioning chemotherapy prior to CAR T cell infusion for patients with CD19+ malignancy in cohort 1. Recommended chemotherapy regimen consists of single agent Cyclophosphamide at a dose of 3000 mg/m2/dose IV over 1 hour or 1500mg/m2/dose x 2 doses given daily over 1 hour given for 2 days (patients may received reduced dose of cyclophosphamide based on the clinical status of the patient at discretion of the treating physician and with written approval by the MSKCC PI of this study). Alternative cyclophosphamide or non-cyclophosphamide-based regimens based on the clinical status of the patient, disease burden, and likely-hood of response may be used at the discretion of the treating physician with written approval by MSKCC PI of the study. Conditioning chemotherapy will not be given prior to infusions # 2 and #3.
Trial: NCT02946801
Drug: Essential oils
RxNorm normalized name: essential oils
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04058587
Drug: Simmitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days).
Trial: NCT02906566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Retinol
Trial: NCT00241332
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02796755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants randomized to this arm will take a placebo, that matches the appearance of 100 mg tablets of riluzole, daily for 8 weeks.
Trial: NCT02400879
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administering remifentanil infusion 0.7-0.8 mcg/kg/min for anesthesia maintenance
Trial: NCT01510574
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x placebo tablets resembling misoprostol taken orally
Trial: NCT00626080
Drug: Insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
Trial: NCT02665910
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets (1 mg, 5 mg, 10 mg)
Trial: NCT02665910
Drug: SHR0302 placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
Trial: NCT02400879
Drug: sevoflurane and sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administering sevoflurane and sufentanil for anesthesia maintenance
Trial: NCT03235050
Drug: MEDI0382 mid dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Trial: NCT03235050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Trial: NCT04219982
Drug: DPI-386 Placebo Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPI-386 Placebo Nasal Gel
Trial: NCT04219982
Drug: Transderm Scop®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transderm Scop®
Trial: NCT00089492
Drug: Optimized Background ARVs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT01706484
Drug: BNO 1016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different dosages of drug and placebo
Trial: NCT03137498
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac 30mg (1ml) intravenous push injection x 1dose
Trial: NCT03603106
Drug: P03277
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: P03277 was administered intravenously with a flow rate of 2 mL/s.
Trial: NCT03603106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: Placebo was administered intravenously with a flow rate of 2 mL/s.
Trial: NCT02286635
Drug: Deflazacort and Clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects. It is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone. Clarithromycin is a semi-synthetic macrolide antibiotic. Clarithromycin is active in vitro against a variety of aerobic and anaerobic gram-positive and gram-negative bacteria as well as most mycobacterium avium complex (MAC) bacteria. Additionally, the 14-OH clarithromycin metabolite also has clinically significant antimicrobial activity. Clarithromycin is indicated for the treatment of mild to moderate infections such as pharyngitis/tonsillitis.
Trial: NCT00775931
Drug: Campath-1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Campath-1H will be administered 0.3 mg/kg subcutaneously per day for three days starting on Day -21 through Day -19.
Trial: NCT00775931
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (50 mg/kg/dose) will be given IV on day -4, -3, -2 and -1 over 2 hours. The total dose to be given over 4 days is 200 mg/kg for cord blood grafts-receiving patients only.
Trial: NCT01988831
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We use placebo pills alike propranolol commercial pills to ensure blindness of the subjects during the study.
Trial: NCT00519818
Drug: Chronocort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
Trial: NCT00590447
Drug: sequential R-CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.~In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy.
Trial: NCT01854684
Drug: Photodynamic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo intraoperative PDT
Trial: NCT00885755
Drug: Standard taxane therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00885755
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg/m2 po bid on days 1-14 of each 3-week cycle (only in patients who have progressed)
Trial: NCT01603654
Drug: low-volume PEG -ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: THe product is used as colon cleanser before colonoscopy. It is supplied as a powder for oral use, to be reconstituted with 2 L of water and drunk as a solution. It consists of 100.0 g macrogol 3350 plus electrolytes (7.5 g sodium sulphate, 2.7 g sodium chloride, 1.0 g potassium chloride) and 4.7 g ascorbic acid.
Trial: NCT00328172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 1356
Trial: NCT01343888
Drug: PegIFN/RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFN/RBV for 48 weeks
Trial: NCT01343888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00751478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00503490
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID
Trial: NCT00335829
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00335829
Drug: embolization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01838993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00854360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA Vehicle Aerosol
Trial: NCT03307720
Drug: Gonadotropin Releasing Hormone Agonists (GNRH-A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.
Trial: NCT04466540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine placebo
Trial: NCT01747941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01064752
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg po bid for 8 weeks
Trial: NCT00034814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme-inducing placebo TID
Trial: NCT00034814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-enzyme-inducing placebo TID
Trial: NCT03985735
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation. Additional cisatracurium （0.05 mg/kg）and fentanyl (30-50 μg at the end of surgery) were used as needed, in accordance with the clinical requirements.
Trial: NCT00506142
Drug: Marqibo® (vincristine sulfate liposomes injection)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.~Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week.
Trial: NCT00644839
Drug: CP-945,598
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of CP-945,598 alone in period 1
Trial: NCT00644839
Drug: CP-945,598
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adminstration of CP-945,598 with omeprazole in period 2
Trial: NCT01366339
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03475134
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Trial: NCT00859833
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myocardial perfusion reserve measured with quantitative MRI during adenosine infusion (0.14 mg/kg/min x 6 minutes).
Trial: NCT04352114
Drug: LY3461767 - SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT04352114
Drug: LY3461767 - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT04352114
Drug: Placebo - SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT03184415
Drug: DWC20155
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT03184415
Drug: DWC20156
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT03184415
Drug: placebo of DWC20155
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT03184415
Drug: placebo of DWC20156
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT02712788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06231212
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen group was given capsules containing 200 mg of ibuprofen
Trial: NCT00000212
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02864810
Drug: [18F]GP1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]GP1 PET/CT imaging for detecting thromboembolism
Trial: NCT01486628
Drug: ND0612
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa and carbidopa solution for subcutaneous administration
Trial: NCT01486628
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution for SC continuous administration
Trial: NCT01276106
Drug: AC-201, 25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, 25mg BID
Trial: NCT01276106
Drug: AC-201, 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, 50mg BID
Trial: NCT01276106
Drug: AC-201, 75mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, 75mg BID
Trial: NCT01276106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID
Trial: NCT00003573
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00649103
Drug: Accupril® Tablets 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg, single dose fasting
Trial: NCT00510276
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a day, by mouth for 12 weeks
Trial: NCT03063658
Drug: Ibuprofen 800 mg
RxNorm normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The first dose of 800 mg intravenous ibuprofen will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
Trial: NCT00005830
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02441894
Drug: PEG-G-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Trial: NCT02441894
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablet Route of administration: oral
Trial: NCT02525679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00685061
Drug: Campath-1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction
Trial: NCT04314622
Drug: Supaglutide
RxNorm normalized name: Supaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04314622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02009579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.
Trial: NCT05204121
Drug: Elpida
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elsulfavirine, capsules
Trial: NCT03218969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01591629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04302116
Drug: Combination therapy with vigabatrin and prednisolone
RxNorm normalized name: prednisolone, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose prednisolone (40 - 60 mg/day) for 1 month combined with vigabatrin treatment (50-150 mg/kg/day) twice daily for 4 months
Trial: NCT01879007
Drug: Factive® Tab / Factive IV
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03622047
Drug: No analgesia labor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No analgesia labor control group
Trial: NCT00245141
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01062867
Drug: ORG25435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intended doses: 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 mg/kg by intravenous infusion over 1 min Up to 25mg/kg by infusion over 30min
Trial: NCT01712347
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
Trial: NCT02935764
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/m2 iv gtt,d1
Trial: NCT00640003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo drug
Trial: NCT00163098
Drug: UK-369,003
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00336713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration (capsules)
Trial: NCT02647671
Drug: Aquamin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 days of Aquamin
Trial: NCT02647671
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 days of placebo
Trial: NCT01871441
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03703505
Drug: [13C6]AG-348
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV microdose of approximately 100 micrograms (mcg), single dose.
Trial: NCT01991379
Drug: MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients should take the study drug with a glass of water. MEK162 can be taken with or without food.
Trial: NCT00527943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets; matching placebo for vorapaxar; loading and maintenance dosing; once daily for at least 1 year
Trial: NCT04476992
Drug: Nitric Oxide-Sessions
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).